Signifier Medical
London, UKFounded 2015
- Series D
Signifier Medical develops and commercialises non-invasive medical technologies for sleep-disordered breathing and snoring. Its eXciteOSA daytime therapy is designed to physiologically retrain the airway to help address the underlying cause of airway collapse.
- RaisedTotal raised
- $58M
- Jul 2021Latest priced round, Jul 2021
- Series D
- Investors
- 8
- Founded
- 2015
- Employees
- 11–50
reccy insights
Signifier Medical’s clearest milestones center on expanding access to eXciteOSA and establishing its regulatory and commercial reach. On Apr 5, 2024, the company announced Medicaid coverage for eXciteOSA in South Carolina. On Jun 10, 2024, it announced an order for 10,000 devices from home medical equipment provider Spectrum Sleep Solutions, a significant commercial milestone. On Feb 5, 2025, eXciteOSA secured European Union Medical Device Regulation certification. On Mar 6, 2025, Signifier introduced a hardware remote control designed to meet CMS requirements and broaden access for Medicare and Medicaid patients. A 2024 study announcement also highlighted research into the cost-effectiveness of neuromuscular therapy. Together, these developments show progress across distribution, reimbursement access, regulatory compliance and evidence-building. The profile identifies eXciteOSA as a daytime therapy for snoring and mild obstructive sleep apnoea, while Snoozeal is also listed as a product. A reported 2026 Sunrise partnership is not included because its associated headline does not substantiate the announcement.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes Signifier Medical distinct
- 01Develops a daytime therapy for sleep-disordered breathing, challenging conventional treatment approaches.
- 02Focuses on non-invasive solutions for sleep apnoea and snoring.
- 03Aims to physiologically retrain airway muscles to help address airway collapse.
- 04Develops products with a multidisciplinary focus on sleep quality and quality of life.
Technology & products2
- eXciteOSA
A daytime neuromuscular electrical stimulation device designed to treat snoring and mild obstructive sleep apnea by strengthening airway muscles.
- Snoozeal
An intra-oral tongue stimulation device used for daytime treatment of snoring and mild obstructive sleep apnea.
- eXciteOSA® daytime therapy for sleep-disordered breathing.
- Neuromuscular electrical stimulation designed to strengthen airway muscles.
- Snoozeal® intra-oral tongue stimulation device.
Recent updates1
- Mar 6, 2025Product launch
A hardware remote control designed to meet CMS requirements for reimbursement, making eXciteOSA® therapy more accessible to Medicare and Medicaid patients.
businesswire.com
Funding
- Series DJul 2021$35MLed by Segulah Medical Acceleration
- Series CSep 2020$10MLed by Alan Howard
- Series BJun 2019$13MLed by The Pritzker Organization
About Signifier Medical
- Products
- eXciteOSA, Snoozeal
- Leadership
- Kieran Gallahue, Executive ChairmanAnshul Sama, Chief Medical OfficerAkhilesh Tripathi, Director, Co-Founder & CEO
- Focus areas
- NeuroTechnology, medical devices, digital health, therapeutics, sleep health, sleep apnoea, respiratory health, snoring
- Headquarters
- London, UK
- Founded
- 2015
- Employees
- 11–50
- Patents granted
- 2